SCHEMBL1044084

SCHEMBL1044084

Cc1ccc(Cn2cc[n+](Cc3ccccc3)c2C)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 6/20 0.71
CA2 P00918 6/20 0.71
EEF2K O00418 2/20 0.58
EEF2 P13639 2/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
PLK4 O00444 1/20 0.58
JAK2 O60674 1/20 0.58
EGFR P00533 1/20 0.58
TYK2 P29597 1/20 0.58
FLT3 P36888 1/20 0.58
BLM P54132 1/20 0.58
ITK Q08881 1/20 0.58
PIM2 Q9P1W9 1/20 0.58
POLB P06746 3/20 0.46
LMNA P02545 2/20 0.46
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1044087 1.00 CA1 (0.71) CA1CA2EEF2KEEF2MEN1
Hydrochloric Acid SCHEMBL1179416 0.98 CA1 (0.74) CA1CA2EEF2KEEF2MEN1
Hydrochloric Acid SCHEMBL1179414 0.98 CA1 (0.74) CA1CA2EEF2KEEF2MEN1
SCHEMBL10325952 0.95 CA1 (0.77) CA1CA2EEF2KEEF2MEN1
SCHEMBL1078732 0.94 CA1 (0.74) CA1CA2EEF2KEEF2MEN1
Bromide SCHEMBL1044433 0.92 CA1 (0.72) CA1CA2EEF2KEEF2MEN1
Hydrochloric Acid SCHEMBL1877207 0.92 CA1 (0.77) CA1CA2EEF2KEEF2MEN1
Water SCHEMBL11782764 0.92 CA1 (0.72) CA1CA2EEF2KEEF2MEN1
SCHEMBL10325611 0.91 CA1 (0.71) CA1CA2EEF2KEEF2MEN1
SCHEMBL5722157 0.83 CA1 (0.62) CA1CA2EEF2KEEF2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110028513-A1 METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2011-02-03 US claimed
EP-2271338-A1 METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS Agency for Science, Technology And Research (SG) 2011-01-12 EP claimed
WO-2009123569-A1 METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2009-10-08 WO claimed
EP-2803356-A1 Method for treating neurological disorders with imidazolium and imidazolinium compounds Agency for Science, Technology and Research (SG) 2014-11-19 EP disclosed
US-20110028513-A1 METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2011-02-03 US disclosed
EP-2271338-A1 METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS Agency for Science, Technology And Research (SG) 2011-01-12 EP disclosed
WO-2009123569-A1 METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028513-A1 METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS SMN1; SMN2, INA, NLN CA1 142/4885CA2 784/4885EEF2K 1187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.